Cognitive Function in a Randomized Trial of Evolocumab

10.1016/S0140-6736(10)61350-5

10.1056/NEJMoa1410489

10.1056/NEJMoa1615664

10.1016/S0002-9343(00)00353-3

10.1016/j.amjmed.2004.07.041

10.1016/j.jacl.2014.02.013

10.1056/NEJMoa1500858

10.1056/NEJMoa1501031

10.1093/eurheartj/ehv563

10.1002/clc.22678

10.1007/7854_2015_5001

10.1016/j.neubiorev.2010.01.012

10.1016/j.neuropharm.2012.07.009

10.4236/ojd.2013.24010

10.12659/MSM.895381

10.1016/j.ahj.2015.11.015

10.1037/0894-4105.22.4.531

Cohen J. Statistical power analysis for the social and behavioral sciences: basic and advanced techniques. 2nd ed. Mahwah, NJ: Lawrence Erlbaum, 1988.

10.1016/j.jalz.2015.06.728

10.1067/mhj.2002.123579

10.1037/a0021134

10.1016/j.drudis.2015.11.003

Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 Extension Study. JAMA Cardiol 2017;2:598-607.

10.1089/cap.2010.0064

10.1016/0028-3932(90)90137-D

10.1111/j.1460-9568.1996.tb01219.x

10.1093/brain/111.3.695

10.1017/S1355617798455073

10.1037/neu0000239

Jessup C. Cambridge Cognition awarded FDA marketing clearance for Cantab mobile. FDA News. January 26, 2017 (http://www.fdanews.com/articles/180219-cambridge-cognition-awarded-fda-marketing-clearance-for-cantab-mobile).